Pharmaxis Of Australia Experiences EU Setback For CF Drug
This article was originally published in PharmAsia News
Executive Summary
Australia's Pharmaxis saw huge stock market losses after the European Union indicated it would deny approval of Bronchitol for treating cystic fibrosis